Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Medroxyprogesterone breast cancer

Low-dose hormone therapy (conjugated equine estrogen 0.45 mg and medroxyprogesterone acetate 1.5 mg/day) has demonstrated equivalent symptom relief and bone density preservation without an increase in endometrial hyperplasia. Whether such lower doses will be safer (cause less venous thromboembolism and breast cancer) remains to be seen. [Pg.359]

Li S, Levesque C, Geng CS, Yan X, Labrie F (1995) Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (El)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Treat 34 147-159... [Pg.166]

Progesterone is synthesized in the corpus luteum in a cycle timed to the menstrual cycle. Synthesis continues should pregnancy develop. Progestins such as megestrol acetate and medroxyprogesterone acetate find use in therapy for metastatic breast cancer. [Pg.277]

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. The Women s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 19 years of age) during 5 years of treatment with oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) relative to placebo.62... [Pg.56]

Case-control study Significantly more cases of breast cancer with depot medroxyprogesterone no link with oral contraceptives (149)... [Pg.184]

Depot medroxyprogesterone acetate should not be used in women with breast cancer, genital cancer, undiagnosed uterine bleeding, or suspected pregnancy (37), but these are merely logical precautions. [Pg.283]

Wander HE, Nagel GA, Blossey HC, Kleeberg U. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). Cancer 1986 58(9) 1985-9. [Pg.284]

Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995 273(10) 799-804. [Pg.284]

World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depo-medroxyprogesterone acetate A multinational study. Lancet 1991 44 419 30. [Pg.1463]

Paul C, Skett DCG, Spears GFS. Depo-medroxyprogesterone (Depo-Provera) and risk of breast cancer. Br Med J 1989 299 759-762. [Pg.1464]

Noguchi, S., Yamamoto, H., Inaji, H., Imaoka, S., and Koyama, H., Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer. Jpn. J. Cancer Res. 80(3), 244-248 (1989). [Pg.223]

See other pages where Medroxyprogesterone breast cancer is mentioned: [Pg.392]    [Pg.863]    [Pg.1318]    [Pg.254]    [Pg.172]    [Pg.458]    [Pg.712]    [Pg.164]    [Pg.281]    [Pg.283]    [Pg.284]    [Pg.290]    [Pg.276]    [Pg.685]    [Pg.392]    [Pg.1693]    [Pg.2227]    [Pg.2228]    [Pg.2932]    [Pg.1068]    [Pg.24]    [Pg.272]    [Pg.1460]    [Pg.1499]    [Pg.1501]    [Pg.1508]    [Pg.189]    [Pg.191]    [Pg.193]   
See also in sourсe #XX -- [ Pg.617 ]



SEARCH



Breasts medroxyprogesterone

Medroxyprogesteron

Medroxyprogesterone

© 2024 chempedia.info